Although several immunotherapeutic regimens are currently evaluated for relapse prevention in AML (41–45), only the combination of HDC/IL-2 has yielded positive results over standard-of-care in a randomized setting (4). This evidence concerns the gene IL2 and acute myeloid leukemia.